Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CONTROL BIONICS LIMITED Share Issue/Capital Change 2021

Feb 22, 2021

64611_rns_2021-02-22_be09d4b5-5095-4e8a-8777-dae85c968aac.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

==> picture [102 x 36] intentionally omitted <==

23 February 2021

ASX ANNOUNCEMENT

Release of shares from escrow

Control Bionics Ltd (ASX: CBL) announces that in accordance with listing rule 3.10A, a total of 14,956,528 ordinary fully paid shares will be released from voluntary escrow on 5 March 2021.

This announcement was authorised by the CEO, Rob Wong.

Investors

Rob Wong - CEO [email protected]

Media

M&C Partners Melissa Hamilton [email protected]

For further information visit the website: https://www.controlbionics.com/

About Control Bionics:

Control Bionics is a technology company which enables a disabled person to use their own neuroelectric signals, from their brain to a muscle, to control communication and movement through smartphones, tablets, computers and robotics, even when that muscle is not fully functional. The Company’s wireless wearable device, ‘ NeuroNode ’, is a world leader in electromyography (EMG), capturing and processing those neuroelectric signals into electronic commands to do everything they would normally do with a keyboard, mouse, joystick or touchscreen. The technology also enables a person to use their eyes to replace a mouse in controlling a cursor on a screen simply by looking where they want the cursor to move; and then to select anything under the cursor, using NeuroNode; providing fast, intuitive communication and control through text, text-to-speech, emails, phone-messaging, web surfing and robotics.

Control Bionics Limited Registered Office: Suite G.03, 171 Union Road, Surrey Hills, VIC, 3127 T: +61 3 9897 3576 W: www.controlbionics.com

ABN: 45 115 465 462